TY  - JOUR
A1  - Wenzel, Mike
A1  - Preißer, Felix Martin
A1  - Wittler, Clarissa
A1  - Höh, Robert Benedikt
A1  - Wild, Peter Johannes
A1  - Tschäbunin, Alexandra
A1  - Bodelle, Boris
A1  - Würnschimmel, Christoph
A1  - Tilki, Derya
A1  - Graefen, Markus
A1  - Becker, Andreas
A1  - Karakiewicz, Pierre I.
A1  - Chun, Felix
A1  - Kluth, Luis
A1  - Köllermann, Jens
A1  - Mandel, Philipp
T1  - Correlation of MRI-lesion targeted biopsy vs. systematic biopsy gleason score with final pathologicalg gleason score after radical prostatectomy
T2  - Diagnostics
N2  - Background: The impact of MRI-lesion targeted (TB) and systematic biopsy (SB) Gleason score (GS) as a predictor for final pathological GS still remains unclear. Methods: All patients with TB + SB, and subsequent radical prostatectomy (RP) between 01/2014-12/2020 were analyzed. Rank correlation coefficient predicted concordance with pathological GS for patients’ TB and SB GS, as well as for the combined effect of SB + TB. Results: Of 159 eligible patients, 77% were biopsy naïve. For SB taken in addition to TB, a Spearman’s correlation of +0.33 was observed regarding final GS. Rates of concordance, upgrading, and downgrading were 37.1, 37.1 and 25.8%, respectively. For TB, a +0.52 correlation was computed regarding final GS. Rates of concordance, upgrading and downgrading for TB biopsy GS were 45.9, 33.3, and 20.8%, respectively. For the combination of SB + TB, a correlation of +0.59 was observed. Rates of concordance, upgrading and downgrading were 49.7, 15.1 and 35.2%, respectively. The combined effect of SB + TB resulted in a lower upgrading rate, relative to TB and SB (both p < 0.001), but a higher downgrading rate, relative to TB (p < 0.01). Conclusions: GS obtained from TB provided higher concordance and lower upgrading and downgrading rates, relative to SB GS with regard to final pathology. The combined effect of SB + TB led to the highest concordance rate and the lowest upgrading rate.
KW  - fusion biopsy
KW  - systematic biopsy
KW  - concordance
KW  - upgrading
KW  - downgrading
KW  - prostate neoplasm
Y1  - 2021
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/61312
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-613121
SN  - 2075-4418
VL  - 11
IS  - 5, art. 882
SP  - 1
EP  - 11
PB  - MDPI
CY  - Basel
ER  -